Please upgrade your browser.
Low government payment rates became the private-sector benchmark, resulting in fragmented care.
Fatigue remains a prominent toxicity with current targeted therapies. Future agents that show better selectivity and potency than current targeted therapies should help to provide better efficacy and tolerability.
A type of normal cell often found in cancerous growths may be the reason for the failure of anti-cancer vaccines.
McKesson will buy all outstanding shares of US Oncology for cash and assume its debt.
Scientists say luminous cells from jellyfish can be used to diagnose cancers deep inside the body.
Lack of KISS1R expression is associated with rapid progression of conventional renal cell carcinomas
The aim of this study was to identify genes associated with the tumor progression.
Recently several lowgrade renal cell tumors, distinct from those recognized by the 2004 World Health Organization classification of renal tumors, have been described.
Andrew Lansley's announcement that cancer patients in England will benefit from a £600 million fund to improve access to cancer drugs over the next three years has been welcomed by the James Whale Fund for Kidney Cancer.
Medical oncologist and cancer researcher Nicholas J. Vogelzang, MD, has been awarded the prestigious Eugene P. Schonfeld Award from the Kidney Cancer Association (KCA).
At ESMO, Seattle Genetics gave investors another reason for optimism, this time following positive data for another wholly owned agent, SGN-75.
|Powered by NeonCRM|